Introduction: Charts for the estimation of cardiovascular risk contribute greatly to clinical decision making in the management of asymptomatic individuals. However, most decisions are taken without consulting the charts. The aim of our study was to record the degree of overestimation or underestimation of cardiovascular risk in everyday clinical practice.
Methods: Seven cases of asymptomatic individuals at different levels of cardiovascular risk as a result of different combinations of risk factors (one at very low, one at very high and five at intermediate risk) were presented in random order to 30 doctors who deal with primary prevention consultations in their daily clinical practice. They were asked if hypolipidaemic therapy was needed and their answers were compared with the recommended management of the current European guidelines on prevention using the risk charts of the European Society of Cardiology.
Results: The mean percentage of agreement was 70%. In the two extreme cases agreement with the guidelines was absolute, but in the intermediate cases it varied widely. Particularly in those cases with cholesterol level 200-240 mg/dl it was just 40%, due either to overestimation or to underestimation of the risk.
Conclusion: In the cases of obviously low or obviously high risk, clinical judgement is in accordance with the guidelines. However, in cases of intermediate risk there is either overestimation of risk with non-indicated prescription of hypolipidaemic treatment, or underestimation of risk with no administration of indicated therapy. The use of risk charts in clinical practice may provide substantial help towards a more objective practice of prevention.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Epicardial Adipose Tissue from Computed Tomography: a Missing Link in Premature Coronary Artery Disease?
Eur Heart J Cardiovasc Imaging
January 2025
Sorbonne Université, unité d'imagerie cardiovasculaire et thoracique, Hôpital La Pitié Salpêtrière (AP-HP), Laboratoire d'Imagerie Biomédicale, INSERM, CNRS, Institute of Cardiometabolism and Nutrition, ACTION Group, Paris, France.
Purpose: Epicardial adipose tissue (EAT) could contribute to the specific atherosclerosis profile observed in premature coronary artery disease (pCAD) characterized by accelerated plaque burden (calcified and non-calcified), high risk plaque features (HRP) and ischemic recurrence. Our aims were to describe EAT volume and density in pCAD compared to asymptomatic individuals matched on CV risk factors and to study their relationship with coronary plaque severity extension and vulnerability.
Materials And Methods: 208 patients who underwent coronary computed tomography angiography (CCTA) were analyzed.
Effect of digital health applications with or without gamification on physical activity and cardiometabolic risk factors: a systematic review and meta-analysis of randomized controlled trials.
EClinicalMedicine
October 2024
Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Center, St. Michael's Hospital, Unity Health Toronto, Toronto, ON M5B 1W8, Canada.
Background: Use of health applications (apps) to support healthy lifestyles has intensified. Different app features may support effectiveness, including gamification defined as the use of game elements in a non-game situation. Whether health apps with gamification can impact behaviour change and cardiometabolic risk factors remains unknown.
View Article and Find Full Text PDFPlatelets as crucial players in the dynamic interplay of inflammation, immunity, and cancer: unveiling new strategies for cancer prevention.
Front Pharmacol
December 2024
Systems Pharmacology and Translational Therapeutics Laboratory, The Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University, Chieti, Italy.
Inflammation plays a critical role in the pathogenesis of various diseases by promoting the acquisition of new functional traits by different cell types. Shared risk factors between cardiovascular disease and cancer, including smoking, obesity, diabetes, high-fat diet, low physical activity, and alcohol consumption, contribute to inflammation linked to platelet activation. Platelets contribute to an inflammatory state by activating various normal cells, such as fibroblasts, immune cells, and vascular cells.
View Article and Find Full Text PDFComprehensive review on neprilysin (NEP) inhibitors: design, structure-activity relationships, and clinical applications.
Front Pharmacol
December 2024
Department of Orthodontics, State Key Laboratory of Oral Diseases, West China School of Stomatology, Sichuan University, Chengdu, Sichuan, China.
Neprilysin (NEP), a zinc-dependent membrane-bound metallopeptidase, regulates various bioactive peptides, particularly in kidneys, vascular endothelium, and the central nervous system. NEP's involvement in metabolizing natriuretic peptides, insulin, and enkephalins makes it a promising target for treating cardiovascular and Alzheimer's diseases. Several NEP inhibitors, such as sacubitril and omapatrilat, have been approved for clinical use, which inhibit NEP activity to prolong the bioactivity of beneficial peptides, thereby exerting therapeutic effects.
View Article and Find Full Text PDFHigh blood pressure is a significant risk factor for cardiovascular diseases and is linked to an increased risk of mild cognitive impairment (MCI). The lack of effective treatments for these conditions highlights the urgent need for novel therapeutic approaches. Recent research suggests that the gut microbiota-brain-gut axis plays a crucial role in the pathogenesis of hypertension and MCI by regulating the nervous, endocrine, and immune systems.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!